Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • c-Myc
    (1)
  • Others
    (8)
Filter
Search Result
Results for "

bodipy 558/568 c12

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    9
    TargetMol | Activity
  • Dye Reagents
    4
    TargetMol | inventory
BODIPY 558/568 C12
T36959158757-84-7
BODIPY 558 568 C12 is a fatty acid-conjugated fluorescent probe for lipid droplets, exhibiting excitation emission maxima of 558 568 nm, respectively. It has been used to monitor the localization and dynamics of lipid droplets in live cells. [1] [2]
    7-10 days
    Inquiry
    C12((±)-2'-hydroxy) dihydro Ceramide (d18:0/12:0)
    T852762377379-54-7
    • Inquiry Price
    8-10 weeks
    Size
    QTY
    BODIPY-C12 Ceramide (d18:1/12:0)
    T361401246355-58-7
    BODIPY-C12 Ceramide (B12Cer) is a fluorescently-tagged form of C12 ceramide, with excitation/emission maxima at 505/540 nm, respectively. It is a fluorescently-labeled sphingolipid and has been utilized for quantifying acid sphingomyelinase activity in the plasma of patients with Niemann-Pick disease.
    • $458
    Backorder
    Size
    QTY
    C12 Galactosylceramide (d18:1/12:0)
    T3685841613-14-3
    C12 Galactosylceramide is a bioactive sphingolipid. It inhibits IL-4 production by 53.84% in EL4 T cells when used at a concentration of 10 μM. C12 Galactosylceramide reduces the growth of human papillomavirus type 16-associated tumors in mice and reduces tumor recurrence following surgical removal or chemotherapy. It also reduces natural killer T cell activity, delays the onset of proteinuria, and improves survival in a mouse model of systemic lupus.
    • $589
    Backorder
    Size
    QTY
    c-Met-IN-12
    T640802426675-70-7
    c-Met-IN-12 is a selective, orally active type II c-Met kinase inhibitor (IC50: 10.6 nM). c-Met-IN-12 is a high inhibitor of AXL, Mer and TYRO3 kinases (>80% inhibition at 1 μM). c-Met-IN-12 can be used as a scaffold to further enhance kinase selectivity. c-Met-IN-12 exhibits anti-tumour activity.
    • $1,520
    6-8 weeks
    Size
    QTY
    C12 3'-sulfo Galactosylceramide (d18:1/12:0)
    T85185852100-88-0
    • Inquiry Price
    8-10 weeks
    Size
    QTY
    c-Fms-IN-12
    T640502145102-33-4
    c-Fms-IN-12 is an FMS kinase inhibitor that also inhibits c-KIT and induces apoptosis in A549 cells. c-Fms-IN-12 is a potential broad-spectrum anti-cancer agent that has demonstrated therapeutic effects in a variety of cancer types.
    • $1,520
    6-8 weeks
    Size
    QTY
    C12 1-Deoxyceramide (m18:1/12:0)
    T850391246298-54-3
    • Inquiry Price
    8-10 weeks
    Size
    QTY
    c-Myc inhibitor 12
    T79439
    Compound 67h, also known as c-Myc inhibitor 12, is a potent inhibitor of c-Myc, exhibiting a pEC50 value of 6.4 [1].
    • Inquiry Price
    Size
    QTY